MEDICENNA THERAPEUTICS CORP (MDNA.CA) Stock Analyst Earnings Estimates
TSX:MDNA - Toronto Stock Exchange - CA58490H1073 - Common Stock - Currency: CAD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A 6,750.66% | N/A 160.02% | N/A 141.16% | N/A -2.89% | N/A 55.07% | ||||||||||
| EBITDA YoY % growth | N/A | -80K | -7.42M -9,175.00% | -4.72M 36.39% | -8.23M -74.36% | -17.36M -110.94% | -22.43M -29.21% | -16.3M 27.33% | -18.67M -14.54% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -200K | -90K 55.00% | -7.43M -8,155.56% | -4.73M 36.34% | -8.24M -74.21% | -17.4M -111.17% | -22.47M -29.14% | -16.3M 27.46% | -18.674M -14.56% | N/A -10.82% | N/A -12.51% | N/A 31.40% | N/A 100.80% | N/A 27,125.19% | N/A -13.14% | N/A 103.39% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A 29.17% | -0.26 0.04% | -0.35 -34.62% | -0.42 -20.00% | -0.19 54.76% | -0.36 -89.47% | N/A 31.06% | N/A -13.70% | N/A 33.13% | N/A | N/A | N/A | N/A |
All data in CAD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.07 2.85% | -0.07 66.00% | -0.08 -63.20% | -0.08 -63.20% | -0.07 -4.99% | -0.08 -19.99% |
| Revenue Q2Q % growth | ||||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -5.727M -19.89% | -5.394M -34.83% | N/A | N/A | N/A | N/A |
All data in CAD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -0.05 | -0.06 | 0.01 | 18.30% |
| Q1 2025 Q2Q % growth | -0.05 -25.00% | -0.06 | 0.01 | 18.30% |
| Q4 2024 Q2Q % growth | -0.20 -233.33% | -0.06 | -0.14 | -256.51% |
| Q3 2024 Q2Q % growth | -0.07 -250.00% | -0.07 | 0.00 | 5.34% |
| Q2 2024 Q2Q % growth | -0.05 -25.00% | -0.07 | 0.02 | 25.73% |
| Q1 2024 Q2Q % growth | -0.04 42.86% | -0.06 | 0.02 | 36.41% |
| Q4 2023 Q2Q % growth | -0.06 | -0.08 | 0.02 | 29.41% |
| Q3 2023 Q2Q % growth | -0.02 77.78% | -0.09 | 0.07 | 78.61% |
| Q2 2023 Q2Q % growth | -0.04 73.33% | -0.07 | 0.03 | 41.90% |
| Q1 2023 Q2Q % growth | -0.07 41.67% | -0.08 | 0.01 | 14.22% |
| Q4 2022 Q2Q % growth | -0.06 45.45% | -0.11 | 0.05 | 44.10% |
| Q3 2022 Q2Q % growth | -0.09 18.18% | -0.13 | 0.04 | 30.01% |
| Q2 2022 Q2Q % growth | -0.15 -87.50% | -0.12 | -0.03 | -26.18% |
| Q1 2022 Q2Q % growth | -0.12 -140.00% | -0.10 | -0.02 | -17.65% |
| Q4 2021 Q2Q % growth | -0.11 -57.14% | -0.11 | 0.00 | -1.74% |
| Q3 2021 Q2Q % growth | -0.11 -57.14% | -0.07 | -0.04 | -59.77% |
| Q2 2021 Q2Q % growth | -0.08 -14.29% | -0.08 | 0.00 | 4.93% |
| Q1 2021 Q2Q % growth | -0.05 | -0.05 | 0.00 | -8.93% |
| Q4 2020 Q2Q % growth | -0.07 -133.33% | -0.05 | -0.02 | -52.51% |
| Q3 2020 Q2Q % growth | -0.07 | -0.07 | 0.00 | 6.41% |
| Q2 2020 Q2Q % growth | -0.07 | -0.07 | 0.00 | 1.96% |
| Q1 2020 Q2Q % growth | -0.05 | -0.08 | 0.03 | 38.73% |
| Q4 2019 Q2Q % growth | -0.03 | -0.11 | 0.08 | 73.26% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2021 Q2Q % growth | 382.5K | -382.5K | -100.00% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 4.76% | -33.34% | -7.35% | -2.81% |
| Revenue | N/A | N/A | N/A | -100% |